Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Influence of gender on receipt of guideline-based antiretroviral therapy in the era of HAART.

Cocohoba JM, Althoff KN, Godfrey R, Palella FJ, Greenblatt RM.

AIDS Care. 2012;24(1):20-9. doi: 10.1080/09540121.2011.592814. Epub 2011 Jul 6.

2.

Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected women.

Cocohoba J, Wang QJ, Cox C, Gange SJ, Cohen M, Glesby M, DeHovitz JA, Greenblatt RM.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):377-83. doi: 10.1097/QAI.0b013e318160d552.

PMID:
18176324
3.

The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts.

Gingo MR, Balasubramani GK, Kingsley L, Rinaldo CR Jr, Alden CB, Detels R, Greenblatt RM, Hessol NA, Holman S, Huang L, Kleerup EC, Phair J, Sutton SH, Seaberg EC, Margolick JB, Wisniewski SR, Morris A.

PLoS One. 2013;8(3):e58812. doi: 10.1371/journal.pone.0058812. Epub 2013 Mar 12.

4.

Predictors of antiretroviral therapy initiation: a cross-sectional study among Chinese HIV-infected men who have sex with men.

Liu Y, Ruan Y, Vermund SH, Osborn CY, Wu P, Jia Y, Shao Y, Qian HZ.

BMC Infect Dis. 2015 Dec 15;15:570. doi: 10.1186/s12879-015-1309-x.

5.
6.

Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts.

Gingo MR, Balasubramani GK, Rice TB, Kingsley L, Kleerup EC, Detels R, Seaberg EC, Greenblatt RM, Holman S, Huang L, Sutton SH, Bertolet M, Morris A.

BMC Pulm Med. 2014 Apr 30;14:75. doi: 10.1186/1471-2466-14-75.

7.

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103.

PMID:
15608532
8.

Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons.

Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, Bing EG, Stein MD, Longshore D, Bozzette SA.

J Gen Intern Med. 2001 Sep;16(9):625-33.

9.

Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study.

Hessol NA, Kalinowski A, Benning L, Mullen J, Young M, Palella F, Anastos K, Detels R, Cohen MH.

Clin Infect Dis. 2007 Jan 15;44(2):287-94. Epub 2006 Dec 12.

PMID:
17173233
10.

Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.

Palella FJ Jr, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, Tracy RP, Elion R.

AIDS. 2010 Jul 17;24(11):1657-65. doi: 10.1097/QAD.0b013e3283389dfa.

11.
12.

Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen.

Turner BJ, Zhang D, Laine C, Pomerantz RJ, Cosler L, Hauck WW.

J Acquir Immune Defic Syndr. 2001 May 1;27(1):20-9.

PMID:
11404516
13.

Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization.

Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, Gifford A, Liu HH, Nakazono TT, Morton S, Bozzette SA, Shapiro MF, Wenger NS.

J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):115-23.

PMID:
11103041
14.

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

European Collaborative Study.

Clin Infect Dis. 2005 Feb 1;40(3):458-65. Epub 2005 Jan 7.

PMID:
15668871
15.

Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice.

Brogly S, Williams P, Seage GR 3rd, Oleske JM, Van Dyke R, McIntosh K; PACTG 219C Team.

JAMA. 2005 May 11;293(18):2213-20.

PMID:
15886376
16.
17.

Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort.

Suárez-García I, Sobrino-Vegas P, Tejada A, Viciana P, Ribas M, Iribarren J, Díaz Menéndez M, Rivero M, Arazo P, Del Amo J, Moreno S; Cohort of the Spanish AIDS Research Network (CoRIS) study group.

HIV Med. 2014 Feb;15(2):86-97. doi: 10.1111/hiv.12078. Epub 2013 Sep 6.

18.

Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus.

Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, Nowicki M, Kovacs A, Cohen M, Muñoz A.

Am J Epidemiol. 2000 Nov 15;152(10):923-33.

PMID:
11092434
19.

Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis.

Ndawinz JD, Chaix B, Koulla-Shiro S, Delaporte E, Okouda B, Abanda A, Tchomthe S, Mboui E, Costagliola D, Supervie V.

J Antimicrob Chemother. 2013 Jun;68(6):1388-99. doi: 10.1093/jac/dkt011. Epub 2013 Feb 7.

PMID:
23391713
20.

Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy.

Stone VE, Mansourati FF, Poses RM, Mayer KH.

J Gen Intern Med. 2001 Jun;16(6):360-8.

Supplemental Content

Support Center